4Tavassoli F A, Devilee P. World Health Organization classification of turnours. Pathology and genetics of tumours of the breast and female genital organs [J]. Lyon: IARC Press, 2003 : 35.
5No authors listed.Tamoxifen for early breast cancer:an overview of the randomised trials.Early Breast Cancer Trialists' Collaborative Group[J].Lancet,1998,351(9114):1451-1467.
6Baum M,Budzar AU,Cuzick J,et al.Anastrozole alone or in combina-tion with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial[J].Lancet,2002,359(9324):2131-2139.
7Baum M,Buzdar A,Cuzick J,et al.Anastrozole alone or in combina-tion with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC(Arimidex,Tamoxifen Alone or in Combination)trial efficacy and safety update analyses[J].Cancer,2003,98(9):1802-1810.
8Dowsett M,Cuzick J,Wale C,et al.Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status:an hypothesis-generating study[J].J Clin Oncol,2005,23(30):7512-7517.
9Sestak I,Cuzick J,Sapunar F,et al.Risk factors for joint symptoms in patients enrolled in the ATAC trial:a retrospective,exploratory analy-sis[J].Lancet Oncol,2008,9(9):866-872.
10Kvinnsland S,Anker G,Dirix LY,et al.High activity and tolerability demonstrated for exemestane in postmenopausal women with metastatic breast cancer who had previously failed on tamoxifen treatment[J].Eur J Cancer,2000,36(8):976-982.
